ReviewChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2014
Subependymal giant cell astrocytoma: current concepts, management, and future directions.
Review in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 32 citations in OpenAlex.
- Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.BMC neurology · 2021Observational
- Neurosurgical treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex: a series of 44 surgical procedures in 31 patients.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2020Article
- Novel management of glioma by molecular therapies, a review article.European journal of translational myology · 2019Article
- Insights into molecular therapy of glioma: current challenges and next generation blueprint.Acta pharmacologica Sinica · 2017Review
- CD99: A potential Diagnostic Marker for Differentiating Sub-ependymal Giant Cell Astrocytoma From Other Mimickers: A Report of Five Cases.Iranian journal of pathology · 2017Article
- Tuberous sclerosis complex: the past and the future.Pediatric nephrology (Berlin, Germany) · 2015Review
- Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management.Wiener klinische Wochenschrift · 2015Review
- Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligase.Acta neuropathologica communications · 2015Article
- A case of tuberous sclerosis complex with concomitant primary hyperparathyroidism due to parathyroid adenoma: a case report.World journal of surgical oncology · 2015Article
- Pathology and genetics of diffuse gliomas in adults.Neurologia medico-chirurgica · 2015Review
Corrections and comments
- Retraction · 2016-04-01Duplication of Text · Euphemisms for Plagiarism ·
- Retracted
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSubependymal giant cell astrocytoma (SEGA) is the most common central nervous system tumor in patients with tuberous sclerosis complex (TSC). SEGAs are generally benign, non-infiltrative lesions, but they can lead to intracranial hypertension, obstructive hydrocephalus, focal neurologic deficits, and even sudden death. DISCUSSION: Surgical resection has been the standard treatment for SEGAs, and it is generally curative with complete resection. However, not all SEGAs are amenable to safe and complete resection. Gamma Knife stereotactic radiosurgery provides another treatment option as a primary or adjuvant treatment for SEGAs, but it has highly variable response effects with sporadic cases demonstrating its efficacy. Recently, biologically targeted pharmacotherapy with mammalian target of rapamycin (mTOR) inhibitors such as sirolimus and everolimus has provided a safe and efficacious treatment option for patients with SEGAs. However, SEGAs can recur few months after drug discontinuation, indicating that mTOR inhibitors may need to be continued to avoid recurrence. Further studies are needed to evaluate the advantages and adverse effects of long-term treatment with mTOR inhibitors. This review presents an overview of the current knowledge and particularly highlights the surgical and medical options of SEGAs in patients with TSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.